Innocoll's Xaracoll (bupivacaine HCl) Receives the US FDA's Approval for the Acute Postsurgical Pain Relief in Adults Following Open Inguinal Hernia Repair
Shots:
- The approval is based on two P-III study (N=610- XARACOLL Arm N=404; PBO Arm N=206) performed as outpatient surgeries in adults across 39 sites in the US.
- Result: Xaracoll provided statistically significant pain relief through 24 hrs. vs PBO- the primary endpoint for both studies. Median time in study 1 (11hrs. vs 1 hrs.) and in study 2 (6hrs. vs 1 hrs.)
- Xaracoll is a unique- non-injectable drug-device combination in the form of a fully bioresorbable collagen implant containing bupivacaine hydrochloride which is placed directly into the surgical site during surgery and- after placement- releases bupivacaine immediately and over time
Ref: Stifel | Image: Stifel
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com